MithraGen, Inc.

MithraGen, Inc.

MithraGen, Inc.

Overview
Date Founded

2000

Headquarters

8030 El Rio Street,Houston, TX 77054-4184

Type of Company

Private

Industries

Pharmaceuticals

Company Description

MithraGen, Inc. develops immunotherapies for the treatment and prevention of cancer and infectious diseases. The company was founded in 2000 and is headquartered in Houston, TX.

Executives & Employees

Founder

Professional

Board of Directors

Founder at OriGene Technologies, Inc.

Chief Operating Officer at Targeted Growth, Inc.

Founder at MithraGen, Inc.

Paths to MithraGen, Inc.
Potential Connections via
Relationship Science
You
MithraGen, Inc.
Investors
Details Hidden

BCM Technologies (BCMT) focuses on early-stage investments in the life sciences sector. The firm seeks opportunities with considerable commercialization potential, clear competitive advantages in existing markets and innovative early entrants in growing niche markets. They provide seed capital for proof-of-concept research and play an active role in structuring and developing start-up companies. BCMT's initial investments are often used to validate a technology through highly-focused research activities. These initial investments frequently precede the recruitment of a management team. The firm prefers to lead seed and first rounds and to continue to co-invest in later rounds.

Details Hidden

Wake Forest University is an institution of higher education dedicated to the pursuit of excellence in the liberal arts and in graduate and professional education. It operates Wake Forest College, a graduate school of arts and sciences, and four professional schools.

Details Hidden

Emerging Technology Partners (ETP) invests in companies that develop drugs to address large unmet clinical needs, develop proprietary technology platforms that address rapidly growing markets, recruit experienced management teams with proven industry expertise and provide substantial returns on invested capital. The firm may invest as early as the seed stage and as late as pre-IPO rounds. ETP typically invests between $500,000 and $3 million in a single round, committing as much as $5 million to a company over a series of financings

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by MithraGen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of MithraGen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and MithraGen, Inc..